# Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

> **NCT05223582** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 34 (estimated)

## Conditions studied

- High-risk Prostate Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Fluzoparib
- **DRUG:** Prednisone
- **DRUG:** Androgen deprivation therapy
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT05223582
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223582, "Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05223582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*